Lippman Evan
EVP, Business Development
Lippman Evan has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Aug 19, 2026.
On the most recent filing, Lippman Evan is listed as EVP, Business Development at TEVA PHARMACEUTICAL INDUSTRIES LTD. Inside the rolling window, Lippman Evan reported no open-market purchases and 2 open-market sales totaling $2.2M in TEVA. The largest disclosed transaction in the window is a sale of 41,658 TEVA shares on May 14, 2026, worth $1.5M.
Companies traded
Other insiders at TEVA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lippman Evan made?
Lippman Evan has filed 2 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Lippman Evan trade?
Lippman Evan has filed SEC Form 4 disclosures for 1 company, including TEVA.
When was Lippman Evan's most recent SEC Form 4 filing?
Lippman Evan's most recent SEC Form 4 filing on Tracefour is dated Aug 19, 2026.
What is Lippman Evan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lippman Evan is listed as EVP, Business Development.
What is Lippman Evan's total buy and sell value in the current window?
Inside the rolling retention window, Lippman Evan bought $0 and sold $2.2M based on SEC Form 4 filings.
What was Lippman Evan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 41,658 TEVA shares on 2026-05-14, worth $1.5M, per SEC Form 4 filings.